TNF-alpha and melphalan modulate a specific group of early expressed genes in a murine melanoma model

Cytokine

Volumn 62, Issue 2, 2013, Pages 217-225

  De Lima, Vladmir Cláudio Cordeiro ^a   De Carvalho, Alex Fiorini ^a   Morato Marques, Mariana ^a   Hashimoto, Vivian Lika ^a   Spilborghs, Graziela Machado Gruner Turco ^a   Marques, Sarah Martins ^c   Landman, Gilles ^a   Torres, Cesar ^a   Braga Ribeiro, Karina ^b   Brentani, Helena ^a   Reis, Luiz F L ^c   Dias, Adriana Abalen Martins ^d  

^a A C CAMARGO CANCER CENTER   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c HOSPITAL SÍRIO LIBANÊS   (Brazil)

^d FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Early expression genes; Melanoma; Melphalan; Microarray; TNF alpha

Indexed keywords

MELPHALAN; OLIGONUCLEOTIDE; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; RNA; ALKYLATING AGENT; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARHGEF6 GENE; ARTICLE; BCL2L11 GENE; CANCER SURVIVAL; CARCINOGENESIS; CONTROLLED STUDY; DLG5 GENE; FLT1 GENE; GENE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HISTOPATHOLOGY; ILK GENE; KIFAP3 GENE; MALE; MELANOMA; MICROARRAY ANALYSIS; MITOSIS RATE; MOUSE; NONHUMAN; PALLD GENE; PARD3 GENE; PECAM1 GENE; POLR1E GENE; PRIORITY JOURNAL; PTPRJ GENE; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; TCFE3 GENE; TUMOR GROWTH; TUMOR NECROSIS; TUMOR VOLUME; ANIMAL; APOPTOSIS; C57BL MOUSE; CANCER TRANSPLANTATION; CELL ADHESION; CELL MOTION; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFECTS; GENETICS; NEOVASCULARIZATION (PATHOLOGY); TREATMENT OUTCOME; TUMOR CELL LINE;

ANIMALIA; MURINAE; MUS;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; GENE EXPRESSION PROFILING; MALE; MELANOMA; MELPHALAN; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84876812744     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2013.02.022     Document Type: Article

References (51)

1. Miller A.J., Mihm M.C. Melanoma. N Engl J Med 2006, 355:51-65.
2. Tsao H., Atkins M.B., Sober A.J. Management of cutaneous melanoma. N Engl J Med 2004, 351:998-1012.
3. Balch C.M., Gershenwald J.E., Soong S.J., Thompson J.F., Atkins M.B., Byrd D.R., et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009.
4. Wheatley K., Ives N., Hancock B., Gore M., Eggermont A., Suciu S. Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat Rev 2003, 29:241-252.
5. Cornett W.R., McCall L.M., Petersen R.P., Ross M.I., Briele H.A., Noyes R.D., et al. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J Clin Oncol 2006, 24:4196-4201.
6. Rossi C.R., Foletto M., Pilati P., Mocellin S., Lise M. Isolated limb perfusion in locally advanced cutaneous melanoma. Semin Oncol 2002, 29:400-409.
7. Grunhagen D.J., de Wilt J.H., van Geel A.N., Eggermont A.M. Isolated limb perfusion for melanoma patients - a review of its indications and the role of tumor necrosis factor-alpha. Eur J Surg Oncol 2006, 32:371-380.
8. Bauer G.B., Povirk L.F. Specificity and kinetics of interstrand and intrastrand bifunctional alkylation by nitrogen mustards at a G-G-C sequence. Nucleic Acids Res 1997, 25:1211-1218.
9. Lienard D., Eggermont A.M., Koops H.S., Kroon B., Towse G., Hiemstra S., et al. Isolated limb perfusion with tumor necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicenter randomized phase II study. Melanoma Res 1999, 9:491-502.
10. Noorda E.M., Vrouenraets B.C., Nieweg O.E., van Geel B.N., Eggermont A.M., Kroon B.B. Isolated limb perfusion for unresectable melanoma of the extremities. Arch Surg 2004, 139:1237-1242.
11. Hayes A.J., Neuhaus S.J., Clark M.A., Thomas J.M. Isolated limb perfusion with melphalan and tumor necrosis factor alpha for advanced melanoma and soft-tissue sarcoma. Ann Surg Oncol 2007, 14:230-238.
12. de Wilt J.H., ten Hagen T.L., de B.G., van Tiel S.T., de Bruijn E.A., Eggermont A.M. Tumor necrosis factor alpha increases melphalan concentration in tumor tissue after isolated limb perfusion. Br J Cancer 2000, 82:1000-1003.
13. Lejeune F.J., Lienard D., Matter M., Ruegg C. Efficiency of recombinant human TNF in human cancer therapy. Cancer Immunol 2006, 6:6.
14. Renard N., Lienard D., Lespagnard L., Eggermont A., Heimann R., Lejeune F. Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumor necrosis factor alpha (rTNF alpha). Int J Cancer 1994, 57:656-663.
15. Ruegg C., Yilmaz A., Bieler G., Bamat J., Chaubert P., Lejeune F.J. Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. Nat Med 1998, 4:408-414.
16. Stoelcker B., Ruhland B., Hehlgans T., Bluethmann H., Luther T., Mannel D.N. Tumor necrosis factor induces tumor necrosis via tumor necrosis factor receptor type 1-expressing endothelial cells of the tumor vasculature. Am J Pathol 2000, 156:1171-1176.
17. Gomes L.I., Silva R.L., Stolf B.S., Cristo E.B., Hirata R., Soares F.A., et al. Comparative analysis of amplified and nonamplified RNA for hybridization in cDNA microarray. Anal Biochem 2003, 321:244-251.
18. Saeed A.I., Sharov V., White J., Li J., Liang W., Bhagabati N., et al. TM4: a free, open-source system for microarray data management and analysis. Biotechniques 2003, 34:374-378.
19. Pfaffl M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001, 29:e45.
20. Moreno-Ramirez D., Cruz-Merino L., Ferrandiz L., Villegas-Portero R., Nieto-Garcia A. Isolated limb perfusion for malignant melanoma: systematic review on effectiveness and safety. Oncologist 2010, 15:416-427.
21. Asher A., Mule J.J., Reichert C.M., Shiloni E., Rosenberg S.A. Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. J Immunol 1987, 138:963-974.
22. Perona R., Montaner S., Saniger L., Sanchez-Perez I., Bravo R., Lacal J.C. Activation of the nuclear factor-kappaB by Rho, CDC42, and Rac-1 proteins. Genes Dev 1997, 11:463-475.
23. Bialkowska K., Kulkarni S., Du X., Goll D.E., Saido T.C., Fox J.E. Evidence that beta3 integrin-induced Rac activation involves the calpain-dependent formation of integrin clusters that are distinct from the focal complexes and focal adhesions that form as Rac and RhoA become active. J Cell Biol 2000, 151:685-696.
24. Filipenko N.R., Attwell S., Roskelley C., Dedhar S. Integrin-linked kinase activity regulates Rac- and Cdc42-mediated actin cytoskeleton reorganization via alpha-PIX. Oncogene 2005, 24:5837-5849.
25. Rosenberger G., Kutsche K. AlphaPIX and betaPIX and their role in focal adhesion formation. Eur J Cell Biol 2006, 85:265-274.
26. Rosenberger G., Jantke I., Gal A., Kutsche K. Interaction of alphaPIX (ARHGEF6) with beta-parvin (PARVB) suggests an involvement of alphaPIX in integrin-mediated signaling. Hum Mol Genet 2003, 12:155-167.
27. Deshpande S.S., Angkeow P., Huang J., Ozaki M., Irani K. Rac1 inhibits TNF-alpha-induced endothelial cell apoptosis: dual regulation by reactive oxygen species. FASEB J 2000, 14:1705-1714.
28. Porchia L.M., Guerra M., Wang Y.C., Zhang Y., Espinosa A.V., Shinohara M., et al. 2-amino-N-{4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-phe nyl} acetamide (OSU-03012), a celecoxib derivative, directly targets p21-activated kinase. Mol Pharmacol 2007, 72:1124-1131.
29. Fang L., Wang Y., Du D., Yang G., Tak K.T., Kai K.S., et al. Cell polarity protein Par3 complexes with DNA-PK via Ku70 and regulates DNA double-strand break repair. Cell Res 2007, 17:100-116.
30. Ma X.Y., Wang H., Ding B., Zhong H., Ghosh S., Lengyel P. The interferon-inducible p202a protein modulates NF-kappaB activity by inhibiting the binding to DNA of p50/p65 heterodimers and p65 homodimers while enhancing the binding of p50 homodimers. J Biol Chem 2003, 278:23008-23019.
31. Wen Y., Yan D.H., Wang B., Spohn B., Ding Y., Shao R., et al. P202, an interferon-inducible protein, mediates multiple antitumor activities in human pancreatic cancer xenograft models. Cancer Res 2001, 61:7142-7147.
32. Freudlsperger C., Thies A., Pfuller U., Schumacher U. The proteasome inhibitor bortezomib augments anti-proliferative effects of mistletoe lectin-I and the PPAR-gamma agonist rosiglitazone in human melanoma cells. Anticancer Res 2007, 27:207-213.
33. Jiang Z., Chu P.G., Woda B.A., Rock K.L., Liu Q., Hsieh C.C., et al. Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study. Lancet Oncol 2006, 7:556-564.
34. Pryor J.G., Bourne P.A., Yang Q., Spaulding B.O., Scott G.A., Xu H. IMP-3 is a novel progression marker in malignant melanoma. Mod Pathol 2008, 21:431-437.
35. Mentrikoski M.J., Ma L., Pryor J.G., McMahon L.A., Yang Q., Spaulding B.O., et al. Diagnostic utility of IMP3 in segregating metastatic melanoma from benign nevi in lymph nodes. Mod Pathol 2009, 22:1582-1587.
36. Mathieu V., Mijatovic T., Van D.M., Kiss R. Gastrin exerts pleiotropic effects on human melanoma cell biology. Neoplasia 2005, 7:930-943.
37. Chang A.J., Song D.H., Wolfe M.M. Attenuation of peroxisome proliferator-activated receptor gamma (PPARgamma) mediates gastrin-stimulated colorectal cancer cell proliferation. J Biol Chem 2006, 281:14700-14710.
38. Carrillo J., Garcia-Aragoncillo E., Azorin D., Agra N., Sastre A., Gonzalez-Mediero I., et al. Cholecystokinin down-regulation by RNA interference impairs Ewing tumor growth. Clin Cancer Res 2007, 13:2429-2440.
39. Takenaka K., Katakura H., Chen F., Ogawa E., Adachi M., Wada H., et al. The ratio of membrane-bound form Flt-1 mRNA to VEGF mRNA correlates with tumor angiogenesis and prognosis in non-small cell lung cancer. Cancer Lett 2007, 246:34-40.
40. Kerber M., Reiss Y., Wickersheim A., Jugold M., Kiessling F., Heil M., et al. Flt-1 signaling in macrophages promotes glioma growth in vivo. Cancer Res 2008, 68:7342-7351.
41. Hiratsuka S., Maru Y., Okada A., Seiki M., Noda T., Shibuya M. Involvement of Flt-1 tyrosine kinase (vascular endothelial growth factor receptor-1) in pathological angiogenesis. Cancer Res 2001, 61:1207-1213.
42. Dikov M.M., Ohm J.E., Ray N., Tchekneva E.E., Burlison J., Moghanaki D., et al. Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation. J Immunol 2005, 174:215-222.
43. Lin Y.L., Liang Y.C., Chiang B.L. Placental growth factor down-regulates type 1 T helper immune response by modulating the function of dendritic cells. J Leukocyte Biol 2007, 82:1473-1480.
44. Straume O., Akslen L.A. Expresson of vascular endothelial growth factor, its receptors (FLT-1, KDR) and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas. Am J Pathol 2001, 159:223-235.
45. Patterson C., Perrella M.A., Endege W.O., Yoshizumi M., Lee M.E., Haber E. Downregulation of vascular endothelial growth factor receptors by tumor necrosis factor-alpha in cultured human vascular endothelial cells. J Clin Invest 1996, 98:490-496.
46. Gille J., Heidenreich R., Pinter A., Schmitz J., Boehme B., Hicklin D.J., et al. Simultaneous blockade of VEGFR-1 and VEGFR-2 activation is necessary to efficiently inhibit experimental melanoma growth and metastasis formation. Int J Cancer 2007, 120:1899-1908.
47. Fischer C., Jonckx B., Mazzone M., Zacchigna S., Loges S., Pattarini L., et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 2007, 131:463-475.
48. Ayers S.D., Nedrow K.L., Gillilan R.E., Noy N. Continuous nucleocytoplasmic shuttling underlies transcriptional activation of PPARgamma by FABP4. Biochemistry 2007, 46:6744-6752.
49. Boiteux G., Lascombe I., Roche E., Plissonnier M.L., Clairotte A., Bittard H., et al. A-FABP, a candidate progression marker of human transitional cell carcinoma of the bladder, is differentially regulated by PPAR in urothelial cancer cells. Int J Cancer 2009, 124:1820-1828.
50. Elmasri H., Karaaslan C., Teper Y., Ghelfi E., Weng M., Ince T.A., et al. Fatty acid binding protein 4 is a target of VEGF and a regulator of cell proliferation in endothelial cells. FASEB J 2009, 23:3865-3873.
51. Panigrahy D., Huang S., Kieran M.W., Kaipainen A. PPARgamma as a therapeutic target for tumor angiogenesis and metastasis. Cancer Biol Ther 2005, 4:687-693.